Floatz logo

Ipilimumab

Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related

National Cancer Institute (NCI)monoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

35 Active assets in the Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 3BB
ETOPOSIDE
Institut de Recherches Internationales Servier
Phase 2BB
Daunorubicin
Institut de Recherches Internationales Servier
Phase 3BB
Decitabine
National Cancer Institute (NCI)
Phase 3BB
ag-120
Institut de Recherches Internationales Servier
Phase 3BB

View all 50 →

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →